{"id":"infliximab-azathioprine","safety":{"commonSideEffects":[{"rate":null,"effect":"Infections (bacterial, viral, fungal)"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Pancreatitis"}]},"_chembl":{"chemblId":"CHEMBL1201581","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Infliximab is a TNF-α inhibitor monoclonal antibody that neutralizes tumor necrosis factor-alpha, a key pro-inflammatory cytokine in IBD pathogenesis. Azathioprine is a purine analog that inhibits T-cell and B-cell proliferation. The combination provides synergistic immunosuppression to induce and maintain remission in inflammatory bowel disease.","oneSentence":"Infliximab blocks TNF-α to reduce inflammation while azathioprine suppresses immune cell proliferation, providing dual immunosuppression for inflammatory bowel disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:43.421Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe Crohn's disease"},{"name":"Moderate to severe ulcerative colitis"}]},"trialDetails":[{"nctId":"NCT05043870","phase":"PHASE4","title":"Combined Immunosuppression for Pediatric Crohn's Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2022-10-10","conditions":"Crohn Disease, Infliximab, Immunosuppression","enrollment":128},{"nctId":"NCT07424040","phase":"NA","title":"The Efficacy and Safety of Infliximab Combination With Azathioprine in Crohn's Disease in Children","status":"NOT_YET_RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2026-03-01","conditions":"Crohn's Diseases, Crohn's Disease in Pediatric Patient","enrollment":154},{"nctId":"NCT06941376","phase":"PHASE2","title":"An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-08-01","conditions":"Relapsing Polychondritis","enrollment":20},{"nctId":"NCT05689879","phase":"PHASE3","title":"Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-03-23","conditions":"Sarcoidosis","enrollment":90},{"nctId":"NCT04259138","phase":"PHASE4","title":"Determination of the Optimal Treatment Target in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2020-02-18","conditions":"Colitis, Ulcerative","enrollment":672},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":"Psoriasis, Atopic Dermatitis","enrollment":10},{"nctId":"NCT06673134","phase":"","title":"Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-12-01","conditions":"Crohn Disease","enrollment":100},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT03681652","phase":"","title":"Post-Operative Crohn's Disease Outcome in Children","status":"RECRUITING","sponsor":"Schneider Children's Medical Center, Israel","startDate":"2019-02-11","conditions":"Crohn Disease","enrollment":100},{"nctId":"NCT03591770","phase":"PHASE4","title":"Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2019-07-31","conditions":"Inflammatory Bowel Diseases","enrollment":15},{"nctId":"NCT06059989","phase":"PHASE3","title":"InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-11-25","conditions":"Inflammatory Disease, Disease Crohn, Bowel Disease","enrollment":158},{"nctId":"NCT06126835","phase":"","title":"A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2024-08-26","conditions":"Ulcerative Colitis","enrollment":2828},{"nctId":"NCT02517684","phase":"PHASE4","title":"Top-down Infliximab Study in Kids With Crohn's Disease","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2015-04","conditions":"Crohn's Disease","enrollment":100},{"nctId":"NCT02332356","phase":"PHASE3","title":"Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease","status":"UNKNOWN","sponsor":"Tokyo Medical and Dental University","startDate":"2014-09","conditions":"Crohn Disease","enrollment":100},{"nctId":"NCT03445624","phase":"","title":"Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-07-01","conditions":"Inflammatory Bowel Diseases","enrollment":60},{"nctId":"NCT05928754","phase":"NA","title":"Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","startDate":"2023-09","conditions":"Non-infectious Uveitis","enrollment":2000},{"nctId":"NCT05014555","phase":"","title":"Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease","status":"UNKNOWN","sponsor":"GI Alliance","startDate":"2023-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":400},{"nctId":"NCT02425852","phase":"PHASE4","title":"A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis","status":"COMPLETED","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2016-12","conditions":"Ulcerative Colitis","enrollment":65},{"nctId":"NCT05813860","phase":"PHASE4","title":"HLADQA1*05 Genotype and the Efficacy of Treatment With Infliximab in Chinese Population Crohn's Disease","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2023-04-30","conditions":"Crohn Disease, Infliximab","enrollment":976},{"nctId":"NCT05584228","phase":"NA","title":"Medical Treatment Versus Surgery in Stricturing Small Bowel Crohn's Disease","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2023-04-01","conditions":"Crohn Disease","enrollment":150},{"nctId":"NCT02177071","phase":"PHASE4","title":"A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy","status":"COMPLETED","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2015-10-09","conditions":"Crohn's Disease","enrollment":211},{"nctId":"NCT05386290","phase":"","title":"A Multicentered Prospective Cohort Study of Chinese IBD Patients","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-07-09","conditions":"Ulcerative Colitis, Crohn Disease","enrollment":200},{"nctId":"NCT04761952","phase":"NA","title":"N-3 Polyunsaturated Fatty Acids Prevent Postoperative Recurrence of Crohn's Disease","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2021-02-13","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Polyunsaturated Acid Lipidosis","enrollment":236},{"nctId":"NCT04196920","phase":"","title":"Methotrexate-associated Anti-TNF Combination Therapy, the Neglected One !","status":"UNKNOWN","sponsor":"University Hospital, Montpellier","startDate":"2019-12-20","conditions":"Chronic Inflammatory Bowel Disease","enrollment":200},{"nctId":"NCT03056924","phase":"","title":"Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":173},{"nctId":"NCT02413047","phase":"NA","title":"Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator","status":"TERMINATED","sponsor":"Indiana University","startDate":"2015-05","conditions":"Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease","enrollment":3},{"nctId":"NCT04109300","phase":"NA","title":"Preemptive HLA Genotyping for the Safe Use of Infliximab-combination Therapy in Inflammatory Bowel Disease","status":"UNKNOWN","sponsor":"Western University, Canada","startDate":"2020-09-01","conditions":"Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease","enrollment":162},{"nctId":"NCT03553472","phase":"","title":"Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2018-01-01","conditions":"Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease","enrollment":97},{"nctId":"NCT03886233","phase":"","title":"Treatment Outcome of Uveitis in Autoimmune Diseases","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-03","conditions":"Autoimmune Uveitis","enrollment":1},{"nctId":"NCT03370601","phase":"NA","title":"Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies in Chronic Inflammatory Diseases","status":"TERMINATED","sponsor":"University Hospital, Lille","startDate":"2017-01-03","conditions":"Inflammatory Bowel Diseases","enrollment":9},{"nctId":"NCT02434133","phase":"","title":"Cross Sectional Study of Vaccine Antibody Response in Inflammatory Bowel Disease Patients","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2015-04","conditions":"Inflammatory Bowel Disease (IBD)","enrollment":110},{"nctId":"NCT03580876","phase":"PHASE4","title":"Addition of Azathioprine in IBD Patients With Immunogenic Failure","status":"UNKNOWN","sponsor":"Védrines, Philippe, M.D.","startDate":"2018-07-23","conditions":"Clinical Failure After Switch","enrollment":90},{"nctId":"NCT03393247","phase":"NA","title":"The Therapy Effect of Azathioprine Initial or 14 Weeks After Combined With Infliximab on CD","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2017-06-01","conditions":"Crohn Disease","enrollment":160},{"nctId":"NCT02356445","phase":"","title":"Use of Immunosuppressive Therapy for Sarcoidosis","status":"UNKNOWN","sponsor":"University of Cincinnati","startDate":"2014-11","conditions":"Sarcoidosis","enrollment":2000},{"nctId":"NCT03151525","phase":"PHASE4","title":"Two Therapeutic Strategies for the Maintenance of Remission in Patients With Ulcerative Colitis","status":"UNKNOWN","sponsor":"Istituto Clinico Humanitas","startDate":"2017-05-08","conditions":"Colitis, Ulcerative","enrollment":100},{"nctId":"NCT00984568","phase":"PHASE3","title":"Conventional Step-Up Versus Infliximab Monotherapy in Patients With Ulcerative Colitis (P05553)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-11","conditions":"Colitis, Ulcerative","enrollment":28},{"nctId":"NCT00537316","phase":"PHASE3","title":"Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Ulcerative Colitis","enrollment":242},{"nctId":"NCT00796250","phase":"PHASE3","title":"Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-11-01","conditions":"Crohn's Disease","enrollment":9},{"nctId":"NCT02453607","phase":"","title":"The Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's Disease","status":"UNKNOWN","sponsor":"Ernest Seidman","startDate":"2014-11-17","conditions":"Inflammatory Bowel Disease, Crohn's Disease","enrollment":225},{"nctId":"NCT00094458","phase":"PHASE3","title":"Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC","status":"COMPLETED","sponsor":"Centocor Ortho Biotech Services, L.L.C.","startDate":"2005-03","conditions":"Crohn Disease","enrollment":508},{"nctId":"NCT02998827","phase":"NA","title":"Thalidomide Results in Diminished Ovarian Reserve in Reproductive Age Female IBD Patients","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2016-11","conditions":"Crohn Disease","enrollment":90},{"nctId":"NCT00132691","phase":"PHASE4","title":"Multicenter Uveitis Steroid Treatment (MUST) Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2005-09","conditions":"Uveitis","enrollment":255},{"nctId":"NCT01802593","phase":"PHASE4","title":"Comparison of 2 Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Thiopurine Failure","status":"TERMINATED","sponsor":"Prof. Arie Levine","startDate":"2013-02","conditions":"Crohn's Disease","enrollment":20},{"nctId":"NCT01880307","phase":"PHASE4","title":"Infliximab Top-down in Pediatric Crohn","status":"TERMINATED","sponsor":"Erasmus Medical Center","startDate":"2013-01","conditions":"Crohn's Disease","enrollment":13},{"nctId":"NCT01505855","phase":"PHASE4","title":"Efficacy Study of Pneumococcal Vaccination in Crohn's Disease","status":"COMPLETED","sponsor":"Kyunghee University Medical Center","startDate":"2011-12","conditions":"Crohn's Disease","enrollment":197},{"nctId":"NCT01860963","phase":"NA","title":"Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-01","conditions":"Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA","enrollment":310},{"nctId":"NCT01752790","phase":"PHASE4","title":"Efficacy and Safety of Top-down Therapy in Pediatric Crohn's Disease","status":"WITHDRAWN","sponsor":"University of Roma La Sapienza","startDate":"2012-12","conditions":"Pediatric Crohn's Disease","enrollment":""},{"nctId":"NCT01613963","phase":"","title":"Causes of Visual Loss in Retinal Disease","status":"UNKNOWN","sponsor":"Royal Surrey County Hospital NHS Foundation Trust","startDate":"2012-05","conditions":"Uveitis, Scleritis","enrollment":2000},{"nctId":"NCT01559142","phase":"PHASE3","title":"Efficacy and Safety of Two Regimens of Maintenance Therapy in Children With Crohn Disease","status":"UNKNOWN","sponsor":"Children's Memorial Health Institute, Poland","startDate":"2008-11","conditions":"Crohn Disease","enrollment":100},{"nctId":"NCT00368264","phase":"PHASE2, PHASE3","title":"TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )","status":"TERMINATED","sponsor":"Medical University of Vienna","startDate":"2006-09","conditions":"Lupus Erythematosus, Systemic, Lupus Nephritis","enrollment":1},{"nctId":"NCT00753103","phase":"PHASE2","title":"Anti-Cytokine Therapy for Vasculitis","status":"COMPLETED","sponsor":"University Hospital Birmingham NHS Foundation Trust","startDate":"2003-01","conditions":"Wegener's Granulomatosis, Renal Limited Vasculitis, Microscopic Polyangiitis","enrollment":37},{"nctId":"NCT00554710","phase":"PHASE4","title":"Top Down Versus Step Up Strategies in Crohn's Disease","status":"COMPLETED","sponsor":"Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW","startDate":"2001-05","conditions":"Crohn's Disease","enrollment":129}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["remicade/imuran"],"phase":"marketed","status":"active","brandName":"infliximab+azathioprine","genericName":"infliximab+azathioprine","companyName":"Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW","companyId":"belgian-inflammatory-bowel-disease-research-and-development-bird-vzw","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Infliximab blocks TNF-α to reduce inflammation while azathioprine suppresses immune cell proliferation, providing dual immunosuppression for inflammatory bowel disease. Used for Moderate to severe Crohn's disease, Moderate to severe ulcerative colitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}